jq1

(+)-JQ-1 (JQ1) 是一种 BET 溴结构域抑制剂，抑制 BRD4(1 2) (IC50=77 33 nM)，具有特异性和可逆性。(+)-JQ-1 可以诱导细胞自噬，抑制细胞增殖。

JQ-1 (carboxylic acid) 是一种细胞渗透性 BRD4 抑制剂，对 BRD4(1) 和 BRD4(2) 的 IC50 分别为 77 和 33 nM。它是一种 (+)-JQ1 衍生物，可作为合成 PROTACs 的前体。

(+)-JQ1 PA 是一种溴结构域和末端外 (BET) 抑制剂 JQ1 的衍生物，IC50 为 10.4 nM。

(R)-(-)-JQ1 Enantiomer 是 (+)-JQ1 的立体异构体。 (+)-JQ1 是一种 BET 溴结构域抑制剂，对BRD4(1 2)的IC50 为 77 和 33 nM。

(+)-JQ1 maleimide是一种探针，由一个与BRD4配体JQ1通过PEG2连接器相连的含有活性的maleimide组成。它可用于COFFEE方法（COvalent Functionalization Followed by E3 Electroporation），在该方法中，(+)-JQ1 maleimide与VHL共价连接后通过电穿孔导入活细胞。E3连接酶在细胞内与BRD4形成复合物，引导其降解。

β-NF-JQ1是一种PROTAC，可将芳烃受体E3 （AhR E3） 连接酶招募到目标蛋白上。β-NF-JQ1使用β-NF 作为AhR 配体靶向含溴odomain（BRD）的蛋白，诱导AhR 和BRD 蛋白相互作用。β-NF-JQ1显示出与蛋白敲除活性相关的强大的抗癌活性 。

ET-JQ1-OH 是一种等位基因特异性的 BET 抑制剂。

(+)-JQ-1 carboxylic acid is a potent bromodomain and extra terminal domain (BET) inhibitor. (+)-JQ-1 carboxylic has potential to be used as a precursor to synthesize PROTACs and other conjugates.

Biotinylated-JQ1 (Biotin-JQ1)为JQ1的一种生物素化衍生物，具有高亲和力地结合至BRD4溴域的能力。该化合物能有效抑制MM1.S多发性骨髓瘤细胞的增殖，其EC50值为0.4 μM。

JQ1-TCO (JQ1-trans-cycloctene) 是一种 BET 抑制剂 JQ1 的衍生物。JQ1-TCO 适用于点击化学，可作为体外和体内的分子探针。

Calanolide B is one of a novel class of HIV-inhibiting coumarins from the tropical rainforest tree, Calophyllum lanigerum.

NICE-01 (AP1867-PEG2-JQ1; AP-PEG2-JQ1)是一款具有双功能的化合物，它通过特异性结合到细胞内特定亚细胞区室中的蛋白质，并以BRD4蛋白的核定位含溴结构域作为诱导，实现将胞浆中的货物输送至细胞核。

KB02-JQ1 is a potent and specific proteolysis targeting chimera (PROTAC) that specifically degrades BRD4, acting as a molecular glue. It does not degrade BRD2 or BRD3. The mechanism of action involves covalent modification of the E3 ligase DCAF16, thereby promoting BRD4 degradation. Importantly, KB02-JQ1 demonstrates enhanced stability and durability in facilitating protein degradation within biological systems. The compound forms a complex with the ubiquitin E3 ligase ligand KB02 through a linker, resulting in the formation of KB02-JQ1[1].

(+)-JQ-1-aldehyde is the aldehyde derivative of (+)-JQ1, commonly used as a precursor for the synthesis of PROTACs targeting the BET bromine domain[1].

JQ-1 (carboxylic acid)-NH-C2-NH-AMPRO-222 是一种包含BRD4的配体与PROTAC接头的化合物，可用于合成PROTACBRD4 Degrader-29。

Cacospongionolide B is isolated from the sponge Fasciospongia cavernosa. The marine sponge natural product cacospongionolide B (1) is one of a class of compounds bearing a g-hydroxybutenolide which are known to inhibit multiple forms of secratory phospholipase A2,1 enzymes believed to initiate a cascade of biological events leading to inflammation.

PNZ5 是一个有效的、异恶唑类的、BET 的广泛抑制剂，有着类似(+)-JQ1 的高选择性和强效作用，其对 BRD4(1) 的 KD 值为 5.43 nM。

TD-428 is a highly specific degrader of BRD4(DC50 of 0.32 nM). TD-428 is a BET PROTAC, which comprises TD-106 (a CRBN ligand) linked to JQ1 (a BET inhibitor). TD-428 efficiently induce BET protein degradation.

β-Naphthoflavone-CH2-Br is an arylhydrocarbon receptor (AhR) ligand. β-Naphthoflavone-CH2-Br used to synthesize the PROTAC β-NF-JQ1.

NH2-PEG3 (PROTAC Linker 35) is a polyethylene glycol (PEG) linker utilized in the synthesis of PROTAC (β-NF-JQ1)[1].

β-Naphthoflavone-CH2-OH (β-NF-CH2-OH) serves as an AhR E3 ligase ligand, forming chimeric molecules when connected to a protein ligand through a linker, resulting in PROTACs or SNIPERs (e.g., β-naphthoflavone-JQ1). These chimeric molecules recruit the AhR E3 ligase complex by incorporating AhR ligands. By inducing ubiquitination-mediated degradation, PROTACs effectively target and degrade cancer-promoting proteins [1].

VH032 thiol (VHL ligand 6) is a VHL ligand that interacts with pan-BET inhibitor JQ1 through a linker to create a PROTAC[1] compound.

SJ46411-Br 作为一种CK1α分子胶 (Molecular Glue) 降解剂，该化合物在口服使用中显示出有效性。它能与CRL2KLHDC2结合，形成复合物以促进合作性同源选择性三元复合物的形成。此外，SJ46411-Br 可通过PROTAC linker 连接BET 配体 JQ1，进而制备相应的PROTACs。

GW841819X is an analogue of (+)-JQ1 and a novel inhibitor of BET bromodomains. GW841819X was a single enantiomer but of undefined chirality at the 4-position of the benzodiazepine ring3. GW841819X and JQ1 were recently discovered that bind to the acetyl-lysine binding pocket of BET bromodomains with Kd ranges from 50 to 370 nM [1]. GW841819X bounded to both the individual BD1 and BD2 domains with affinities of 46 and 52.5 nM, respectively. GW841819X-Brd3 interaction was estimated to be around 70 nM4. GW841819X displayed activity in vivo against NUT-midline carcinoma, multiple myeloma, mixed-lineage leukemia, and acute myeloid leukemia1. It also potent induced the ApoA1 reporter gene with an EC50 of 440 nM. It had very little effect on LDL-R luciferase activity at the concentrations at which it induces ApoA1 expression, suggesting that the effect is indeed specific3. GW841819X competed directly with GATA1 site for BD1 binding and also specifically blocked the interaction between Brd3 and acetylated GATA14. Recent findings reported that GW841819X are chose as an interest compound to further develop into potential drugs against diseases including cancer, HIV infection and heart disease2.